The Vanderbilt scientists and others analyzed in an animal model a new method developed at The Scripps Research Institute (TSRI) in La Jolla, Calif., for designing artificial proteins capable of stimulating an immune response against RSV.
The virus, which worldwide causes nearly 7 percent of all deaths among children ages 1 month to 1 year and is the leading cause of hospitalizations among children under 2, has been notoriously resistant to vaccine-design strategies.
"This project is the first work in which a protein that was designed on a computer has been shown to work as a vaccine candidate for a human pathogen," said Vanderbilt's James Crowe, M.D., Ann Scott Carell Professor and a leading RSV researcher.
"We believe this will be one of the principal ways that vaccines are designed and made in the future," said Crowe, also professor of Pediatrics and Pathology, Microbiology and Immunology.
TSRI scientists, led by senior author William Schief, Ph.D., used a "rational design" approach that focused on specific binding areas (epitopes) on the virus.
Virtually all existing viral vaccines use whole (killed or weakened) virus particles or entire viral proteins to stimulate antibody reactions. These vaccines display virtually the same large set of viral epitopes that the immune system would encounter during a natural infection. Yet some viruses, including RSV, conceal their vulnerable epitopes.
Scientists can sift through blood samples of virus-exposed patients to find the rare, "broadly neutralizing" antibodies that hit those vulnerable epitopes. They also know how to map the precise atomic structures of these antibodies and their corresponding epitopes using X-ray crystallography.
"What we haven't been able to do is to take that information about broadly neutralizing antibodies and their epitopes and translate it into effective, epitope-focused vaccines," lead author Bruno Correia, Ph.D., a member of the Schief laboratory at the time of the study, said in a news release.
The TSRI scientists developed a new software app, "Fold from Loops," to design proteins that folded around their functional fragments more naturally in a way that mimicked the viral epitope and which could serve as a key component of an effective vaccine.
In rhesus macaque monkeys, whose immune systems are quite similar to humans,' the designer "immunogen" proteins showed great promise. After five immunizations, 12 of 16 monkeys were producing robust amounts of antibodies that could neutralize RSV in the lab dish.
Analyses of the animals' immune responses were performed in the laboratories of Philip Johnson, M.D., at Children's Hospital in Philadelphia, and by Crowe and postdoctoral fellow John T. Bates, Ph.D., in the Vanderbilt Vaccine Center, which Crowe directs.
Former Vanderbilt faculty member Barney Graham, M.D., Ph.D., chief of the Viral Pathogenesis Laboratory at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, also participated in the analyses.
Having proven the principle of epitope-specific design, Schief and his colleagues now hope to produce a working RSV vaccine. "We're also trying to improve this protein design method further and apply it to other vaccine projects, including HIV and influenza vaccines," he said in a news release.
Craig Boerner | Vanderbilt University
The herbivore dilemma: How corn plants fights off simultaneous attacks
09.02.2016 | Boyce Thompson Institute for Plant Research
Shedding Light on Bacteria
09.02.2016 | Albert-Ludwigs-Universität Freiburg im Breisgau
Exceeding critical temperature limits in the Southern Ocean may cause the collapse of ice sheets and a sharp rise in sea levels
A future warming of the Southern Ocean caused by rising greenhouse gas concentrations in the atmosphere may severely disrupt the stability of the West...
Indications of light-induced lossless electricity transmission in fullerenes contribute to the search for superconducting materials for practical applications.
Superconductors have long been confined to niche applications, due to the fact that the highest temperature at which even the best of these materials becomes...
Researchers at King’s College London and the Wellcome Trust Sanger Institute in the United Kingdom have for the first time demonstrated a direct link between the Wbp2 gene and progressive hearing loss. The scientists report that the loss of Wbp2 expression leads to progressive high-frequency hearing loss in mouse as well as in two clinical cases of children with deafness with no other obvious features. The results are published in EMBO Molecular Medicine.
The scientists have shown that hearing impairment is linked to hormonal signalling rather than to hair cell degeneration. Wbp2 is known as a transcriptional...
Pollens, the bane of allergy sufferers, could represent a boon for battery makers: Recent research has suggested their potential use as anodes in lithium-ion batteries.
"Our findings have demonstrated that renewable pollens could produce carbon architectures for anode applications in energy storage devices," said Vilas Pol, an...
Automobiles increase the mobility of their users. However, their maneuverability is pushed to the limit by cramped inner city conditions. Those who need to...
09.02.2016 | Event News
02.02.2016 | Event News
26.01.2016 | Event News
09.02.2016 | Event News
09.02.2016 | Materials Sciences
09.02.2016 | Power and Electrical Engineering